Tradewinds Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Tradewinds Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100	Closed	-$2.79K	–	486
2023 Q3	$2.79K	Hold	100	–	–	﹤0.01%	321
2023 Q2	$3.41K	Hold	100	–	–	﹤0.01%	305
2023 Q1	$3.01K	Hold	100	–	–	﹤0.01%	311
2022 Q4	$2.82K	Hold	100	–	–	﹤0.01%	334
2022 Q3	$3K	Hold	100	–	–	﹤0.01%	295
2022 Q2	$3K	Sell	100 -2	-2%	-$70	﹤0.01%	304
2022 Q1	$5K	Hold	102	–	–	﹤0.01%	557
2021 Q4	$6K	Hold	102	–	–	﹤0.01%	547
2021 Q3	$8K	Hold	102	–	–	﹤0.01%	492
2021 Q2	$9K	Hold	102	–	–	﹤0.01%	492
2021 Q1	$9K	Buy	+102	New	+$10.1K	﹤0.01%	465

Other funds holding ARKG

MMEA

Main Management ETF Advisors San Francisco, California $3.3B AUM 33.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Tradewinds Capital Management's ARKG Position: Q4 2023 in Review

Tradewinds Capital Management sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2023, closing a stake of 100 shares — an estimated $2.79K sold.

Tradewinds Capital Management first reported a position in ARKG in Q1 2021 and held it in 11 quarters. The position peaked at $9K in Q2 2021. 300 funds tracked by Wall St. Rank hold ARKG as of Q4 2023.

Tradewinds Capital Management reported no remaining ARK Genomic Revolution ETF position as of Q4 2023 after selling out during the quarter.
Tradewinds Capital Management sold 100 ARK Genomic Revolution ETF shares in Q4 2023, an estimated $2.79K.
Tradewinds Capital Management first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 11 quarters.
Tradewinds Capital Management's ARK Genomic Revolution ETF position peaked at $9K in Q2 2021.
300 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2023.

Based on Tradewinds Capital Management's 13F filing for Q4 2023, filed 1 Feb 2024.